Data in Clinical Cancer Research Article Shows that Peregrine's Lead VEA Compound Enhances Efficacy of Multiple Chemotherapeutic Agents

National Institute of Allergies and Infectious Diseases to Test Tarvacin(TM) for Antiviral Potential

Peregrine Pharmaceuticals' Tarvacin(TM) Shows Significant Anti-Viral Activity

Peregrine Pharmaceuticals Announces Third Quarter Financial Results

'Clinical Cancer Research' Article States Tarvacin(TM) Equivalent Inhibits Tumor Growth by up to 90% in Multiple Tumor Models

Journal of Clinical Oncology Publishes Significant Anti-Tumor Activity of Tumor Necrosis Therapy for Treating Patients With Advanced Lung Cancer

Avid Bioservices Signs Commercial Manufacturing Contract With Halozyme Therapeutics

Peregrine Pharmaceuticals Presents Data at 7th International Symposium on Anti-Angiogenic Agents

Prominent Scientist Joins Peregrine Pharmaceuticals' Scientific Resource Board

Peregrine Pharmaceuticals Adds Two Prominent Virologists to Its Scientific Resource Board